CN202951096U - Antibacterial catheter - Google Patents
Antibacterial catheter Download PDFInfo
- Publication number
- CN202951096U CN202951096U CN 201220056703 CN201220056703U CN202951096U CN 202951096 U CN202951096 U CN 202951096U CN 201220056703 CN201220056703 CN 201220056703 CN 201220056703 U CN201220056703 U CN 201220056703U CN 202951096 U CN202951096 U CN 202951096U
- Authority
- CN
- China
- Prior art keywords
- particle
- conduit
- antibacterial
- antibiotic property
- catheter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Disclosed is an antibacterial catheter. Even if antibacterial agent particles cannot be dissolved in solvent, the antibacterial catheter also can restrain antibacterial agent particles from dropping off from the surface of the catheter, can maintain the antibacterial property in the long term, and has excellent blood adaptability. The antibacterial catheter is a covered layer which is composed of the antibacterial agent particles and is formed on the surface of at least a vessel inner inserting part of the catheter, the sum of percentages of the sizes of the antibacterial agent particles with the particle diameters being 0.04-1.0um and in the antibacterial agent particles which form the cover layer is above 97%, and surface roughness of the covered layer is arithmetic average roughness (Ra) and is less than 0.1 um.
Description
Technical field
This utility model relates to a kind of antibiotic property conduit, especially designs a kind of endovascular central venous catheter that is retained in.
Background technology
As one of antibiotic property conduit, can exemplify central venous catheter.This central venous catheter is the utensil that a kind of skin that inserts central venous catheter at subclavian vein or jugular vein thrusts section, the top ends Preserving time of central venous catheter is used in upper large vein.
And, for fear of central venous catheter, may make the skin of antibacterial by central venous catheter thrust section or inner chamber and enter in body and produce the situation that antibacterial infects, and make central venous catheter there is antibiotic property.
In addition, owing to the central venous catheter Preserving time may being used in vivo, therefore wish to keep for a long time antibiotic property.
Here, as the manufacture method of the antibiotic property conduit that is endowed antibiotic property, it is the manufacture method in macromolecular compound etc. that patent documentation 1 discloses a kind of raw material that antibacterial is sneaked into to conduit.In addition, patent documentation 2 also discloses following manufacture method: conduit is immersed in the solution that is dissolved with antibacterial, and makes the solution drying of adhering to, use the surface of the layer coating conduit of antibacterial.
In addition, according to the manufacture method of above-mentioned antibiotic property conduit, when using the antibacterial of same amount, and sneak into the situation that antibacterial manufactured compare in macromolecular compound etc., in the situation that catheter surface coated antibacterial agent layer, the antibacterial that catheter surface distributes is more.Therefore, the situation at catheter surface coated antibacterial agent layer has advantages of that antibiotic property is high.
Patent documentation 1: Japanese kokai publication hei 5-220216 communique
Patent documentation 2: Japanese kokai publication hei 11-290449 communique
But, in the coating process of putting down in writing at patent documentation 2, for example, while using silver zeolite particle etc. to be insoluble to antibacterial particle coating conduit surperficial of solvent, because the silver zeolite particle is insoluble to solvent, therefore, can be fixed on the surface of conduit under larger state at particle diameter, make surperficial roughness become large.Therefore, in use, when inserting in blood vessel by conduit, the silver zeolite particle may occur and come off, can not keep the situation of antibiotic property from catheter surface.On the other hand, by the conduit Preserving time in blood vessel the time, the surface that conduit may occur forms the situation that thrombosis, blood adaptability descend.
In addition, in the situation that the particle diameter of silver zeolite particle is too small, because particle can condense in solvent, particle in solvent disperses unstable, and therefore, the silver zeolite particle can't be overlayed on the surface of conduit equably, the situation larger with particle diameter is the same, and the surface at conduit during use can form thrombosis.In addition, the silver zeolite particle is overlayed on unevenly on catheter surface and also can be caused that antibiotic property descends.
The utility model content
Therefore, this is made clearly in view of the above problems, its purpose is to provide a kind of antibiotic property conduit, even be insoluble to the antibacterial particle of solvent, this antibiotic property conduit and manufacture method thereof also can suppress antibacterial and come off, keep for a long time antibiotic property from catheter surface, and have excellent blood adaptability.
For solving above-mentioned problem, antibiotic property conduit of the present utility model is, the surface of inserting position at least blood vessel of conduit is formed with the coating consisted of the antibacterial particle, characteristics are, the antibacterial particle that forms described coating comprises the antibacterial particle that particle diameter is 0.04～1.0 μ m, and the surface roughness of described coating is that arithmetic average roughness (Ra) is less than 0.1 μ m.
Adopt said structure, due to the ratio of the antibacterial particle of the specified diameter that forms the catheter surface coating, in prescribed limit, therefore the surface roughness of coating is in prescribed limit,, while inserting and being retained in blood vessel, can keep chronically antibiotic property and antithrombotic.
In addition, in described antibiotic property conduit, described antibacterial particle comprises year silver-colored silicon oxide particle or silver zeolite particle or a silver particles.
In addition, in described antibiotic property conduit, described conduit has: the body with tube shape of inner chamber; The top ends of the tube shape engaged with the tip side of body; And the collector device engaged with the base end side of body.
In addition, in described antibiotic property conduit, described conduit also has: the connection tube engaged with the collector device; And the joint engaged with the base end side of connection tube.
Adopt said structure, the antibacterial particle of the silver that contains the antibacterial action excellence due to use, therefore further kept antibiotic property.
The manufacture method of antibiotic property conduit of the present utility model comprises: the antibacterial particle is distributed in organic solvent, with pulverizer, the particle size distribution of described antibacterial particle is modulated and make the dispersion pulverizing process containing antimicrobial; Make the described interior operation of inserting the surface at position of at least blood vessel that is attached to conduit containing antimicrobial; And make to be attached to the described operation containing the antimicrobial drying on described catheter surface, the particle size distribution be modulated in described dispersion pulverizing process, the percent by volume sum of the antibacterial particle that its particle diameter is 0.04～1.0 μ m is more than 97%, and the percent by volume sum of the antibacterial particle that particle diameter is 0.04～0.2 μ m is below 70%.
Adopt above-mentioned steps, due in disperseing pulverizing process, modulate the particle size distribution that makes containing the antibacterial particle of antimicrobial in prescribed limit with pulverizer, thus, through adhering to operation and drying process, make catheter surface form the coating that the antibacterial particle by the particle diameter with prescribed limit forms, and the surface roughness that makes this coating is in prescribed limit.Consequently, can produce the antibiotic property conduit of long-term maintenance antibiotic property and antithrombotic.
In addition, in the manufacture method of antibiotic property conduit, the particle size distribution be modulated in described dispersion pulverizing process, the peaked particle diameter of the expression of the percent by volume of its described antibacterial particle (mode diameter) is preferably more than 0.08 μ m.
Adopt above-mentioned steps, due to the most common diameter of antibacterial particle in prescribed limit, therefore, be easy to modulate the percent by volume sum of the antibacterial particle that particle size range is 0.04～0.2 μ m, make the antibacterial particle of coating particle diameter, and the surface roughness of coating in prescribed limit.Consequently, can manufacture the antibiotic property conduit of further maintenance antibiotic property and antithrombotic.
In addition, the manufacture method of antibiotic property conduit, described antibacterial particle preferably comprises and carries at least any in silver-colored silicon oxide particle, silver zeolite particle and silver particles.
Adopt above-mentioned steps, the antibacterial particle of the silver that contains the antibacterial action excellence due to use, therefore, can manufacture the antibiotic property conduit of further maintenance antibiotic property.
The utility model effect:
Adopt above this utility model, a kind of antibiotic property conduit and manufacture method thereof can be provided, even be insoluble to the antibacterial particle of solvent, also can suppress the antibacterial particle and come off from catheter surface, but long term maintenance conduit antibiotic property, and there is excellent blood adaptability.
The accompanying drawing explanation
Fig. 1 means the figure of unitary construction of the central venous catheter of this utility model embodiment.
Fig. 2 means the figure of the particle size distribution containing antimicrobial of using in embodiment 1.
Fig. 3 means the figure of the particle size distribution containing antimicrobial of using in embodiment 2.
Fig. 4 means the figure of the particle size distribution containing antimicrobial of using in comparative example 1.
Fig. 5 means the figure of the particle size distribution containing antimicrobial of using in comparative example 2.
Fig. 6 means the figure of the particle size distribution containing antimicrobial of using in comparative example 3.
Fig. 7 means the figure of the particle size distribution containing antimicrobial of using in comparative example 4.
Fig. 8 is the figure schematically shown for the structure of the adaptive TAT quantum of output of evaluating blood measuring device.
Symbol description:
1 central venous catheter
2 bodies
3 top ends
4 collector devices
5 connection tubes
6 joints
The specific embodiment
Embodiment to antibiotic property conduit of the present utility model describes.
The antibiotic property conduit is that a kind of surface of inserting position at least blood vessel of conduit is formed with the coating consisted of the antibacterial particle, and it will form the particle diameter of the antibacterial particle of coating, the roughness that reaches the coating surface is defined in prescribed limit.Below, each structure is described.
In the antibiotic property conduit, be formed with the conduit of coating so long as the conduit used in the insertion blood vessel gets final product, its structure is not particularly limited, and for example, in the situation that use antibiotic property conduit of the present utility model to be used as central venous catheter, has following structure.
As shown in Figure 1, central venous catheter 1 has: the body 2 of tube shape, and it has the inner chamber (not shown) of mobile medicinal liquid etc.; The top ends 3 of tube shape, its tip side with body 2 engages; Collector device 4, its base end side with body 2 engages; Connection tube 5, it engages with collector device 4 for injecting medicinal liquid; And joint 6, its base end side with connection tube 5 engages.
This central venous catheter 1 is a kind of for from subclavian vein or jugular vein, inserting top ends 3 (body 2), body 2 is kept somewhere in upper large vein etc., carry out the medical apparatus of high calorie transfusion, medicament delivery and blood sampling etc. with connection tube 5, this central venous catheter 1 use forms for the macromolecular material of antibiotic property conduit all the time.As macromolecular material, can use polyurethane, polrvinyl chloride, polyamide, polyolefin, polyester, silicones etc.
In addition, in central venous catheter 1, the interior position of inserting of blood vessel that what is called is formed with the coating (not shown) consisted of the antibacterial particle refers to body 2 and top ends 3, and the surface of inserting position in so-called blood vessel refers to the body 2 of tube shape and inner surface and the outer surface of top ends 3.
In the antibiotic property conduit, the antibacterial particle that forms coating can be any in inorganic series antibacterial agent particle, organic system antibacterial particle, for example, can exemplify and carry silver-colored silicon oxide particle, silver zeolite particle, silver particles, copper particle, platinum micropartical, Titanium particles, zinc oxide particle, tungsten oxide particle, silver sulfadiazine, CNT, year silver-colored CNT, silver-plated CNT etc.And the antibacterial particle is containing on the silver-colored this point of antibacterial action excellence, preferably comprise and carry at least any in silver-colored silicon oxide particle, silver zeolite particle and silver particles.
The percent by volume sum of the antibacterial particle that in addition, in the antibacterial particle of formation coating, particle diameter is 0.04～1.0 μ m need to be more than 97%.In the particle diameter of the antibacterial particle that forms coating, when the ratio of particle diameter in 0.04～1.0 μ m scope is less than 97%, coating just has the oversize grain that particle diameter surpasses 1.0 μ m, it is large that the surface roughness of coating becomes, when using conduit, the antibacterial particle can come off from catheter surface, and catheter surface can form thrombosis.Here, particle diameter 0.04 μ m is the measurement boundary value of the particles diameter measuring device (particles distribution instrument) sold on the market.In addition, the particle diameter that forms the antibacterial particle of coating is controlled by particle size distribution adjusted to the antibacterial particle containing antimicrobial that forms coating in the manufacture at the antibiotic property conduit and is realized (with reference to dispersion pulverizing process described later).
In the antibiotic property conduit, the surface roughness of coating should be arithmetic average roughness (Ra) and is less than 0.1 μ m.The surface roughness of coating (Ra) is at 0.1 μ m when above, and it is large that the surface roughness of coating becomes, and when using conduit, the antibacterial particle can come off from catheter surface, and can form thrombosis at catheter surface.In addition, the control of the surface roughness of coating (Ra) is realized (with reference to dispersion pulverizing process described later) by particle size distribution adjust to the antibacterial particle containing antimicrobial that forms coating in the manufacture at the antibiotic property conduit.
Below, the embodiment of the manufacture method of antibiotic property conduit of the present utility model is described.
Manufacture method of the present utility model comprises and disperses pulverizing process, adheres to operation and drying process, and it will disperse the particle size distribution that contains the antibacterial particle of antimicrobial in pulverizing process to be defined in prescribed limit.The following describes each operation.
Disperse pulverizing process:
Disperseing pulverizing process is a kind ofly to make the antibacterial particle be distributed in organic solvent, with pulverizer, the particle size distribution of antibacterial particle is modulated the operation of making containing antimicrobial.And, in disperseing pulverizing process, the particle size distribution that contains the antibacterial particle of antimicrobial is modulated with pulverizer, thereby make the percent by volume sum of the antibacterial particle that particle diameter is 0.04～1.0 μ m in prescribed limit, and the percent by volume sum that makes the antibacterial particle that particle diameter is 0.04～0.2 μ m is in prescribed limit.In addition, preferably, mean that in particle size distribution the percent by volume of antibacterial particle is that peaked particle diameter (the most common diameter) is in prescribed limit.
In disperseing pulverizing process, organic solvent for the making containing antimicrobial, its solvent species from the conductive pipe surface that is suitable for subsequent processing to adhere to, can make the antibacterial particle to be dispersed in the solvent solvent selected, be preferably N-Methyl pyrrolidone (NMP), oxolane (THF), DMF (DMF), dimethyl acetylamide (DMA) and Ketohexamethylene etc.In addition, when when adhering to the operation use containing antimicrobial, preferably with appropriate solvent, diluted, used.As retarder thinner, use solvent, methanol and the ethanol etc. that use in described dispersion treatment.In addition, for the antibacterial particle because cross as has been described like that, therefore omit statement.In addition, containing the amount of the antibacterial particle in antimicrobial, according to the desired antibiotic property of antibiotic property conduit and the adaptive degree of blood, suitably set, but, in the situation that use the antibiotic property conduit as central venous catheter, be preferably 0.1～3wt/V%.
In disperseing pulverizing process, as long as particle size distribution can be adjusted to prescribed limit for the pulverizer of the particle size distribution of adjusting the antibacterial particle, be not particularly limited, but be preferably jet pulverizer.And, by controlling the pulverization conditions of pulverizer, the particle size distribution of modulating the antibacterial particle.In the situation that make pulverizer with jet pulverizer, pulverization conditions is preferably 50～200MPa, 50～1000Pass.
The particle size distribution of antibacterial particle should be: the percent by volume sum of the antibacterial particle that particle diameter is 0.04～1.0 μ m is more than 97%, and the percent by volume sum of the particle diameter antibacterial particle that is 0.04～0.2 μ m is below 70%.In addition, in particle size distribution, the most common diameter of preferred antimicrobial agents particle is more than 0.08 μ m.
In particle size distribution, when the percent by volume sum of the antibacterial particle that particle diameter is 0.04～1.0 μ m is less than 97%, have the oversize grain that particle diameter surpasses 1.0 μ m on the coating formed in rear operation, it is large that the surface roughness of coating becomes, when using conduit, the antibacterial particle can come off from catheter surface, and can form thrombosis at catheter surface.Here, particle diameter 0.04 μ m is the measurement boundary value of the particles distribution instrument of market sale.
In addition, in particle size distribution, when the percent by volume sum of the antibacterial particle that particle diameter is 0.04～0.2 μ m surpasses 70%, be dispersed in the antibacterial particle little containing the particle diameter in antimicrobial and become many, can condense again after pulverizing with pulverizer and form the oversize grain that particle diameter is large.Consequently, on the coating formed, have oversize grain in rear operation, it is large that the surface roughness of coating becomes, and when using conduit, the antibacterial particle can come off from catheter surface, and can form thrombosis at catheter surface.In addition, the formation of the coating on conductive pipe surface becomes inhomogeneous, and this situation is also to make the thrombosed main cause of catheter surface.
In addition, in particle size distribution, when the most common diameter of antibacterial particle is less than 0.08 μ m, the percent by volume sum of the antibacterial particle that above-mentioned particle diameter is 0.04～0.2 μ m becomes and is easy to surpass 70%, the less antibacterial particle be dispersed in containing the particle diameter in antimicrobial becomes many, can condense after pulverizing with pulverizer again and easily forms the oversize grain that particle diameter is large.Consequently, at the coating formed, easily have oversize grain in rear operation, it is large that the surface roughness of coating becomes, and when using conduit, the antibacterial particle can come off from catheter surface, and easily at catheter surface, forms thrombosis.In addition, in the formation of the coating of catheter surface, become inhomogeneous, be easy to form thrombosis.
Adhere to operation:
Adhere to operation and be the surface attachment of inserting position at least blood vessel that makes conduit and modulated the operation containing antimicrobial of particle size distribution in aforementioned operation.And the conductive pipe surface attachment is preferably conduit is immersed in containing carrying out in antimicrobial containing the adherence method of antimicrobial.In addition, as adherence method, except the dipping, can also for the spraying etc.In addition, containing the adhesion amount of antimicrobial, according to the desired antibiotic property of antibiotic property conduit and the adaptive degree of blood, suitably set, control by suitable adjustment dip time, coating weight etc.
Drying process:
Drying process is the operation containing the antimicrobial drying that makes to be attached to catheter surface in aforementioned operation.And, in drying process, by drying, make solvent from containing the antimicrobial evaporation, form the coating formed by the antibacterial particle at catheter surface.In addition, drying can be by heat treated, be placed in the lower either type of room temperature carries out, and according to the solvent species containing antimicrobial, suitably selects.
Embodiment:
Below, embodiment of the present utility model etc. is described.
Embodiment No.1, reference example No.7:
The particle powder (mass percent of silver content is 20%) that makes to carry silver-colored silicon oxide particle is distributed in N-Methyl pyrrolidone (NMP) with the ratio of 5wt/v%, disperse (stirrings) afterwards instantaneous precipitation larger cohesion piece (untreated liquid) is arranged.To condense piece with jet pulverizer (ordinary light commercial firm system) and pulverize (180MPa, 800Pass) and this 20ml untreated liquid is become containing antimicrobial, with particles distribution instrument (COULTER commercial firm system), measure particle size distribution.Its result is illustrated in Fig. 2, table 1.
Should contain antimicrobial with methanol (Me) dilution, and with the mixed solvent (mixing ratio 1: 1) of N-Methyl pyrrolidone and methanol, it was modulated into to the antimicrobial that contains of 1wt/v%.Then, with polyurethane, (Japanese Miractran (Japanese: ミ ラ Network ト Application) commercial firm's system, trade name " E990 ") forms the pipe (conduit that is equivalent to reference example No.7) that length is 30cm.This pipe is immersed in containing in antimicrobial, then carries out drying and make conduit (conduit that is equivalent to embodiment No.1).Measure the surface roughness (arithmetic average roughness Ra) of this conduit with laser microscope.Its result is illustrated in table 1.In addition, for the conduit of reference example No.7, measure surface roughness (arithmetic average roughness Ra) similarly, its result is illustrated in table 1.
Embodiment No.2:
The particle powder (the silver content mass percent is 20%) that makes to carry silver-colored silicon oxide particle is distributed in oxolane (THF) with the ratio of 5wt/v%, and after disperseing (stirring), instantaneous precipitation has larger cohesion piece (untreated liquid).To condense piece with jet pulverizer (ordinary light commercial firm system) and pulverize (100MPa, 400Pass) and this 20ml untreated liquid is become containing antimicrobial, with particles distribution instrument (COULTER commercial firm system), measure particle size distribution.Its result is illustrated in Fig. 3, table 1.
Should contain antimicrobial with the THF dilution, and it was modulated into to the antimicrobial that contains of 1wt/v%.Then, with polyurethane, (Japanese Miractran (Japanese: ミ ラ Network ト Application) commercial firm's system, trade name " E990 ") forms the pipe that length is 30cm, and this pipe is immersed in containing in antimicrobial, then carries out drying and makes conduit.Measure the surface roughness (arithmetic average roughness Ra) of this conduit with laser microscope.Its result is illustrated in table 1.
Comparative example No.3:
Use the untreated liquid of embodiment No.1 to be used as, containing antimicrobial, producing conduit the samely with embodiment No.1.In addition, the particle size distribution of untreated liquid, the surface roughness of conduit (arithmetic average roughness Ra) are also measured the samely with embodiment No.1, and its result is illustrated in Fig. 4, table 1.
Comparative example No.4:
With pearl mill apparatus (manufacture of AIMEX commercial firm), the untreated liquid of embodiment No.1 is pulverized to (2000rpm, 3 hours), in addition, modulated in the same manner containing antimicrobial with embodiment No.1.Containing antimicrobial, with embodiment No.1, made in the same manner conduit with this.In addition, containing the particle size distribution of antimicrobial, the surface roughness (arithmetic average roughness Ra) of conduit, also with embodiment No.1, measured in the same manner, its result is illustrated in Fig. 5, table 1.And, confirmed that this can condense in the time of standing 1 hour containing antimicrobial again.
Comparative example No.5:
Use the untreated liquid of embodiment No.2 to be used as, containing antimicrobial, having made conduit the samely with embodiment No.2.In addition, the particle size distribution of untreated liquid, the surface roughness of conduit (arithmetic average roughness Ra) are also measured the samely with embodiment No.2, and its result is illustrated in Fig. 6, table 1.
Comparative example No.6:
With jet pulverizer (ordinary light commercial firm system), the untreated liquid of embodiment No.1 is pulverized to (180MPa, 40Pass), in addition, modulate containing antimicrobial the samely with embodiment No.1.Containing antimicrobial, made conduit with this samely with embodiment No.1.In addition, containing the particle size distribution of antimicrobial, the surface roughness (arithmetic average roughness Ra) of conduit, also measured, its result is illustrated in Fig. 7, table 1 the samely with embodiment No.1.
Then, the conduit for embodiment No.1, embodiment No.2, comparative example No.3～6 and reference example No.7 carries out the blood Adaptability Evaluation in the following method, and its result is illustrated in table 1.
The blood adaptability:
]In Fig. 8,801 is the blood bag, and 802 is three-way valve (blood sampling), and 803 is conduit, 804,806 is check valve, and 805 is internal diameter 6mm/PVC pipe, and 807 is pump, K1 is 37 ℃, heparinization people's fresh whole blood (blood) of 50ml, and K2 is blood, and S1 is mandrel.
By the system shown in Fig. 8, conduit is carried out the blood circulation experiment of 60min.After circulation, the index of having measured the thrombosis degree is TAT (thrombin-antithrombin complex III complex) generation.The measured value that can say the TAT generation is less, and thrombosis more is difficult to form, and the blood adaptability is more excellent.
Table 1
Annotate: NMP:N-methyl pyrrolidone, THF: oxolane
Annotate: JM: jet pulverizer, BM: pearl mill apparatus
Annotate: regional A: the percent by volume sum that particle diameter is 0.04～1.0 μ m
Annotate: regional B: the percent by volume sum that particle diameter is 0.04～0.2 μ m
Annotate: TAT: thrombin-antithrombin complex III complex
As shown in table 1, confirm: meet No.1, the No.2 of the embodiment of this utility model important document and do not form the reference example No.7 of coating and the comparative example No.3 of discontented unabridged version utility model important document～6, blood adaptability excellence.
Claims (4)
1. an antibiotic property conduit, the surface of inserting position at least blood vessel of conduit is formed with the coating consisted of the antibacterial particle, it is characterized in that,
The antibacterial particle that forms described coating comprises the antibacterial particle that particle diameter is 0.04～1.0 μ m,
The surface roughness of described coating is that arithmetic average roughness (Ra) is less than 0.1 μ m.
2. antibiotic property conduit as claimed in claim 1, is characterized in that, described antibacterial particle comprises year silver-colored silicon oxide particle or silver zeolite particle or a silver particles.
3. antibiotic property conduit as claimed in claim 1 or 2, is characterized in that, described conduit has: the body with tube shape of inner chamber; The top ends of the tube shape engaged with the tip side of body; And the collector device engaged with the base end side of body.
4. antibiotic property conduit as claimed in claim 3, is characterized in that, described conduit also has: the connection tube engaged with the collector device; And the joint engaged with the base end side of connection tube.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011064607A JP5787566B2 (en) | 2011-03-23 | 2011-03-23 | Antibacterial catheter and method for producing the same |
| JP2011-064607 | 2011-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202951096U true CN202951096U (en) | 2013-05-29 |
Family
ID=47181882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201220056703 Expired - Lifetime CN202951096U (en) | 2011-03-23 | 2012-02-21 | Antibacterial catheter |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP5787566B2 (en) |
| CN (1) | CN202951096U (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017138715A1 (en) * | 2016-02-11 | 2017-08-17 | 주식회사 아폴론 | Foley catheter and method for manufacturing same |
| KR20170094753A (en) * | 2016-02-11 | 2017-08-21 | (주)아폴론 | Method for forming Foley for Catheter |
| KR20170094755A (en) * | 2016-02-11 | 2017-08-21 | (주)아폴론 | Method for manufacturing Foley Catheter |
| CN108601923A (en) * | 2016-02-11 | 2018-09-28 | 阿波罗恩有限公司 | Foley catheter and its manufacturing method |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102152574B1 (en) * | 2016-02-11 | 2020-09-08 | (주)아폴론 | Composition for Foley Catheter |
| KR102582229B1 (en) * | 2021-06-02 | 2023-09-25 | 주식회사 메디트 | Antibacterial Hand-held Scanner |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4592920A (en) * | 1983-05-20 | 1986-06-03 | Baxter Travenol Laboratories, Inc. | Method for the production of an antimicrobial catheter |
| EP2108383A1 (en) * | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Medical devices with an anti-bacterial polyurethane urea coating |
-
2011
- 2011-03-23 JP JP2011064607A patent/JP5787566B2/en active Active
-
2012
- 2012-02-21 CN CN 201220056703 patent/CN202951096U/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017138715A1 (en) * | 2016-02-11 | 2017-08-17 | 주식회사 아폴론 | Foley catheter and method for manufacturing same |
| KR20170094753A (en) * | 2016-02-11 | 2017-08-21 | (주)아폴론 | Method for forming Foley for Catheter |
| KR20170094755A (en) * | 2016-02-11 | 2017-08-21 | (주)아폴론 | Method for manufacturing Foley Catheter |
| CN108601923A (en) * | 2016-02-11 | 2018-09-28 | 阿波罗恩有限公司 | Foley catheter and its manufacturing method |
| KR102090471B1 (en) | 2016-02-11 | 2020-03-23 | (주)아폴론 | Method for manufacturing Foley Catheter |
| KR102090477B1 (en) | 2016-02-11 | 2020-03-23 | (주)아폴론 | Method for forming Foley for Catheter |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012200274A (en) | 2012-10-22 |
| JP5787566B2 (en) | 2015-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN202951096U (en) | Antibacterial catheter | |
| US7820284B2 (en) | Microbe-resistant medical device, microbe-resistant polymeric coating and methods for producing same | |
| JP5820804B2 (en) | Method for producing antibacterial medical device | |
| US10172978B2 (en) | Medical device for short time use with quickly releasable antibacterial agent | |
| ES2611105T3 (en) | Three-dimensional nanocomposite materials consisting of a polysaccharide matrix and metal nanoparticles, preparation and use thereof | |
| EP1879552B1 (en) | Drug delivery compositions comprising a polyelectrolyte complex within a polymeric matrix | |
| US20130004560A1 (en) | Polymer Nanofilm Coatings | |
| US10709819B2 (en) | Method for coating catheters with a layer of antimicrobial agent | |
| CN103751854B (en) | Antibiotic medical catheter | |
| Croes et al. | Antimicrobial and anti-thrombogenic features combined in hydrophilic surface coatings for skin-penetrating catheters. Synergy of co-embedded silver particles and heparin | |
| FitzGerald | Suppression of scarring in peripheral nerve implants by drug elution | |
| EP2055328B1 (en) | Stent with a base body made of a bioinert metallic implant material | |
| Zhou et al. | Delivering nitric oxide with poly (n-butyl methacrylate) films doped with S-nitroso-N-acetylpenicillamine | |
| Karademir et al. | Antimicrobial Surface Functionality of PEG Coated and AgNPs Immobilized Extracorporeal Biomaterials | |
| JP2010179031A (en) | Method of manufacturing antibacterial medical instrument and antibacterial medical instrument | |
| Negut et al. | Advances in Antimicrobial Coatings for Preventing Infections of Head-Related Implantable Medical Devices | |
| JPH04231062A (en) | Antimicrobial medical product | |
| TR2022020810T2 (en) | A SYSTEM WHERE SHAPE MEMORY ALLOY IS USED IN DRUG RELEASE | |
| US20240102195A1 (en) | Method of coating a metallic substrate with a polymeric bioactive coating | |
| US20230293781A1 (en) | System for shape memory alloy enabled drug release | |
| JP5639481B2 (en) | Antibacterial medical device manufacturing method and antibacterial medical device | |
| CN116212123A (en) | Preparation method and application of antibacterial hydrogel | |
| Lyu et al. | Drug–Material Interactions, Materials Selection, and Manufacturing Methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20130529 |
|
| CX01 | Expiry of patent term |